Effect of Tumor Micronecrosis on Postoperative Transcatheter Arterial Chemoembolization in Patients With Hepatocellular Carcinomas

Micronecrosis is a novel pathological feature of hepatocellular carcinoma (HCC). This study was aimed at evaluating the effect of tumor micronecrosis on postoperative transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinomas, and further exploring the value of micronecrosis for guiding TACE in HCC management.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Carcinoma, Hepatocellular Adenocarcinoma Carcinoma Digestive System Diseases Digestive System Neoplasms Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial

Sex eligibility

All sexes

Study type

Observational

Primary location

the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(1) pathologically confirmed HCC (2) achievement of R0 resection.

Exclusion criteria

(1) simultaneous presence of other tumors ; (2) receipt of preoperative anti-tumoral treatments; (3) concurrent treatment with other antitumoral therapies in combination with TACE; (4) tumor necrosis that could be observed by gross examination; (5) a lack of necessary preoperative laboratory test results.

Treatment and study plan

Transcatheter arterial chemoembolization

Procedure

transcatheter arterial chemoembolization after liver resection

Primary outcomes

overall survival

Time frame: after liver resection until June 1, 2020

the number of months from the date of surgery to the date of the last follow-up visit or time of death.

Secondary outcomes

disease-free survival

Time frame: after liver resection until June 1, 2020

the number of months from the date of surgery to the date of first confirmable recurrence or death

Sponsors and collaborators

Lead sponsor

Zhejiang University

Other

Registry information

Official study title

The Guiding Value of Tumor Micronecrosis for Using Postoperative Transcatheter Arterial Chemoembolization in Patients With Hepatocellular Carcinomas

Important dates

Study start: 2020
Primary completion: 2022
Study completion: 2022
First posted: Apr 28, 2022
Registry last updated: Feb 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed